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Background - Traditionally ovarian tumours have been surgically removed because of the 
presumed risk of complications. Large prospective studies on long-term follow-up of adnexal 
masses are lacking. The aim is to estimate the cumulative incidence of cyst accidents (torsion, 
rupture) and malignancy during the first two years of follow-up of adnexal masses classified 
as benign using ultrasonography.  
 
Methods – This is a 2-year interim analysis of a multicentre international prospective cohort 
study (IOTA5 study) involving consecutive patients with an adnexal mass selected for surgery 
or conservative management after ultrasound assessment. Follow-up of patients managed 
conservatively is ongoing. This interim analysis focuses on patients selected for conservative 
management of an adnexal mass judged to be benign on ultrasound on the basis of subjective 
assessment of ultrasound images. Patients were recruited consecutively between January 1st 
2012 and March 1st 2015 in 36 centres. We analysed follow-up information until June 30th 
2017. All patients had at least one adnexal mass and underwent a standardised transvaginal 
ultrasound examination. The primary endpoint is cumulative incidence of spontaneous 
resolution of the mass, and torsion, cyst rupture, borderline or invasive malignancy confirmed 
surgically in patients with a newly diagnosed adnexal mass. 
 
Findings – The analysis comprises 3144 patients selected for conservative management of an 
adnexal mass judged to be benign on ultrasound. For 221 patients (7%) we have incomplete 
data, 336 (11%) patients were operated on before a planned follow-up scan was performed. 
Of 2587 patients with follow-up, 668 (26%) had a mass already being followed at the same 
centre before recruitment, and 1919 (74%) presented with a new mass (not already in follow-
up in the centre before recruitment; median follow-up of the latter 27 months). The 
cumulative incidence of spontaneous resolution within 2 years of follow-up (n=1919) was 
20·2% (95% CI, 18·4-22·1), that of invasive malignancy, borderline tumour, torsion and cyst 
rupture was 0·4% (95% CI, 0·1-0·6%), 0·3% (95% CI, <0·1-0·5%), 0·4% (95% CI, 0·1-
0·7%), and 0·2% (95% CI, <0·1-0·4%), respectively. 
 
Interpretation – Knowledge that the risk of malignancy and acute complications is low if 
adnexal masses with benign ultrasound morphology are managed conservatively is of great 
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value when counselling patients and supports conservative management of adnexal masses 
classified as benign using ultrasound. 
 




The management of an adnexal mass is an important clinical problem. It is estimated that 
more than 200,000 women undergo exploratory surgery for a pelvic mass in the USA each 
year, and that 22,240 patients will be diagnosed with ovarian cancer in 2018.1,2 Due to the 
widespread use of diagnostic imaging, including ultrasound, adnexal masses are often 
detected incidentally, and most of them will prove to be benign.3,4 Traditionally most women 
with an adnexal mass undergo surgery. The probable reason for this liberal use of surgery is a 
concern that an adnexal mass may prove to be malignant or that it will undergo malignant 
transformation if left in situ. A further issue is the presumed risk of torsion or rupture of the 
mass. Women are likely to benefit from surgical removal of an adnexal mass if there are 
bothersome symptoms related to it, or from being referred to a gynaecologic oncologist for 
evaluation before surgery if there is a suspicion of malignancy.5 However, surgical 
interventions for asymptomatic patients with benign adnexal masses are expensive and also 
associated with complications. The reported rate of severe surgical complications for 
incidentally detected benign adnexal masses varies from 3.5% to as high as 15%.4,6 
Conservative management might be an alternative for asymptomatic benign adnexal masses, 
but large studies describing long-term follow-up are lacking, and so the natural history of 
adnexal masses left in situ is largely unknown. This lack of knowledge makes the 
management of adnexal masses in asymptomatic women or women with minimal symptoms 
clinically challenging. 
In contrast to Magnetic Resonance and Computed Tomography imaging, ultrasonography is 
cheap, harmless, accessible, requires no preparation of patients and there are no contra-
indications. Both subjective assessment of ultrasound images and the International Ovarian 
Tumour Analysis (IOTA) ultrasound algorithms are excellent methods to discriminate 
between benign and malignant adnexal masses.7-9 This would suggest that ultrasound is the 
preferred method for following up patients with an adnexal mass judged not to require 
surgery. To date, however, it is unknown whether a benign appearance on ultrasound means it 
is safe to manage an adnexal mass expectantly. 
The aim of this study is to estimate the risk of adverse events (including a diagnosis of 
malignancy, cyst rupture, or torsion) during ultrasound follow-up of adnexal masses with 




Study design and participants 
This is  a 2-year interim analysis of the IOTA5 study, an international multicentre prospective 
cohort study (for details see IOTA5 project plan in Supplementary material p19). IOTA5 
includes consecutive patients with an adnexal mass selected for surgery or conservative 
management after ultrasound assessment. The patients were recruited from January 1st, 2012 
to December 31st, 2016. The study will continue at least until five years of follow-up for each 
conservatively managed patient is achieved. The primary aim of the IOTA5 study is to 
estimate the risk of adverse events during ultrasound follow-up of adnexal masses with 
benign ultrasound morphology. We obtained approval from the ethics committee of the 
University Hospitals Leuven as the coordinating centre (B32220095331/S51375), and the 
local ethics committee of each contributing centre. 
Due to lack of evidence in the literature, it was desirable to have an interim analysis while the 
study was ongoing, in order to estimate the incidence of complications during follow-up. 
Most false negative results should be detected within one year of follow-up. During the 
second year of follow-up malignant transformations could become more frequent. Hence, we 
here report outcomes during the first two years of ultrasound follow-up of patients selected 
for conservative management with an adnexal mass judged to be benign on ultrasound. For 
this interim analysis we include patients recruited between January 1st, 2012 and March 1st, 
2015 and follow-up data until June 30th, 2017. Thirty-six centres in 14 countries recruited 
patients to the study. The contributing centres were either oncology referral centres (tertiary 
centres with a specific gynaecologic oncology unit) or other types of centre. Patients were 
eligible if they were at least 18 years old at recruitment, and presented with at least one 
adnexal mass (ovarian, para-ovarian or tubal) on ultrasound examination. Pending informed 
consent, local clinicians examined the patient following a standardised research protocol. 
Exclusion criteria were lesions presumed to be physiological if <3 cm in largest diameter, 
denial or withdrawal of informed consent. Pregnancy was not an exclusion criterion. Patients 
could be recruited into the study even if they had an adnexal mass that was already being 
followed up in the recruitment centre. If so, the time in follow-up before inclusion was 
registered. 
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Because no accurate estimates of study outcomes could be found in the literature we stated in 
the IOTA5 project plan that we aimed to collect at least 3000 patients with an adnexal mass 
and at least 1000 patients with an adnexal mass managed conservatively. 
 
Procedures 
The ultrasound examiners recruiting patients collected clinical information and performed a 
transvaginal ultrasound examination following the standardised research protocol. They used 
grey scale and colour or power Doppler ultrasound to characterize the morphology and 
vascularisation of the adnexal mass and described the ultrasound results using IOTA 
terminology.10 There were no requirements about level of experience of the ultrasound 
examiners, but all investigators had passed the IOTA certification test11 and were required to 
submit five representative ultrasound images for approval of image quality before recruiting 
patients. The ultrasound examiner classified each mass using subjective assessment of the 
ultrasound images as benign, borderline or malignant and specified the degree of certainty 
with which the diagnosis was made (certainly - probably - uncertain). The presumed histology 
was also registered. The ultrasound diagnoses were based on knowledge of the typical 
ultrasound appearance of benign, borderline and malignant lesions and that of different types 
of specific adnexal pathology.12 When the examiner detected multiple masses, the dominant 
mass was defined as the mass with the most complex ultrasound morphology. If multiple 
masses had similar morphology, the largest mass or the one best accessible with ultrasound 
was denoted dominant. The dominant mass was used for outcome assessment. The ultrasound 
examiner suggested surgery or conservative management on the basis of the ultrasound 
diagnosis (benign or malignant, borderline tumours considered malignant) and the patient´s 
symptoms. Conservative management included ultrasound and clinical follow-up at intervals 
of three, six and then every 12 months. At follow-up visits clinical information including 
symptoms was collected and a transvaginal ultrasound examination following the research 
protocol was performed. In this analysis we include masses that were judged to be probably or 
certainly benign on the basis of subjective evaluation of the ultrasound images and that were 
selected for conservative management by the ultrasound examiner. Ultimately, the treating 
clinician decided upon management. 
We collected the data through a secure electronic platform developed for the study (IOTA5 
Study Screen; astraia Software, Munich, Germany). Patients automatically received a unique 
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identifier upon enrolment. We encrypted all data communication to ensure data security. A 
team of biostatisticians and expert ultrasound examiners performed data cleaning. Data 
cleaning included sending queries to participating centres to retrieve missing information. At 
the local centres a standardised questionnaire (Supplementary material p12) was used to 
accrue missing information by telephone contact to patients and managing clinicians. 
 
Outcomes 
Follow-up continued until one of three study outcomes was observed: spontaneous resolution 
(the examiner could no longer visualize the mass in the absence of any surgical intervention), 
surgical removal of the mass, or death due to any cause. The indication for surgery was based 
on local practice. We classified the reason for surgery into three groups: 1) suspicion of 
malignancy, 2) pain, and 3) patient request, fertility concerns, opportunistic or prophylactic 
removal (Supplementary material p2). We classified the findings at surgery into six groups: 1) 
invasive malignancy, 2) borderline tumour, 3) torsion, 4) cyst rupture, 5) minor mass 
complications (inflammation/infection or adhesions), or 6) no mass complications 
(Supplementary material p2). Histological examination was performed at the local centre. We 
did not include central pathology review, because we previously observed little differences in 
reported outcomes between local and central pathology reports.13 We classified malignant 
tumours according to the criteria recommended by the International Federation of 
Gynaecology and Obstetrics.14 
The main study endpoints were cumulative incidence of spontaneous resolution of the mass, 
surgical confirmation of torsion or cyst rupture and histological confirmation of invasive 
malignancy or a borderline tumour within two years of study entry in patients with a new 
mass (not already in follow-up in the centre before recruitment).  
 
 
Statistical analysis  
We calculated the follow-up time from the recruitment visit until the study outcome. In the 
absence of a study outcome, we calculated follow-up time until the last visit, and included 
these patients as censored observations in the analysis. We estimated median follow-up with 
the reverse Kaplan-Meier method.15 We analysed follow-up data using cumulative incidence 
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curves in the context of competing risks survival analysis.16 Cumulative incidence curves for 
a specific outcome classified other outcomes as competing events. We summarized 
cumulative incidence curves by reporting the estimated cumulative incidence with 95% 
confidence intervals at 12 months and 24 months of follow-up. Some patients underwent 
surgery before they had undergone a follow-up scan, even though the ultrasound examiner 
had suggested conservative management. We did not include these patients in the survival 
analysis, but we describe the reason for surgery and the histological outcome for them 
separately. For other patients, we did not have any information after the initial visit. These 
patients provide no information and were not included in the survival analysis. We present 
descriptive statistics separately for patients without any information (i.e. patients lost to 
follow-up before any follow-up scan was performed) and for patients with information after 
recruitment (i.e. patients with follow-up scans or operated on before a follow-up scan was 
performed) to check for differences in background information between these groups. 
The main analysis is the survival analysis performed only on patients with a new mass (a 
mass that was not already in follow-up in the centre before recruitment). This provides the 
most correct estimates of cumulative incidences by avoiding survival bias (masses already in 
follow-up before recruitment are a selected group with probably a higher proportion of benign 
and stable tumours).  To provide transparent reporting of all data in our study, we also show 
the results of survival analysis performed on all patients. 
Finally, we performed a subgroup analysis for the variable menopausal status at recruitment, 
where we report cumulative incidences at 12 and 24 months of follow-up. If menopausal 
status was uncertain (for example because of hysterectomy), we classified patients aged 50 
years or older as postmenopausal. 
The statistical analysis was performed with R version 3.4.4.  
 
 
Role of the funding source  
The funders had no role in the study design, data collection, data analysis, data interpretation, 
or the writing of the report. The corresponding author had full access to all the data in the 




In total, 8519 patients were recruited into IOTA5 between January 1st, 2012 and March 1st, 
2015 (Figure 1). We excluded 25 patients following withdrawal of consent. The ultrasound 
examiner suggested conservative management for 4567 patients, of which 4447 (97%) were 
judged to have a mass that was probably or certainly benign (Supplementary material p3-4). 
The ultrasound examiner suggested conservative management for 3602 (49%) of the patients 
with a new mass, of which 3494 (97%) were judged to have a mass that was probably or 
certainly benign. We excluded 17 centres because they recruited too few patients or provided 
follow-up data of insufficient quality (Supplementary material p3-4). Of the 3144 patients in 
the remaining 19 centres (Table 1), 734 (23%) patients had a mass that was already being 
followed in the recruitment centre before inclusion and 2410 (77%) had a new mass (Table 2).  
Median age of the 3144 patients was 48 years (interquartile range 37-63), 1429 patients (45%) 
were postmenopausal, 1912 (61%) had a dominant mass that was a unilocular cyst (one cyst 
locule, no solid components) and 444 (14%) had a dominant mass containing solid 
components (Table 2).10 For 221/3144 (7%) patients, we have no follow-up information after 
the recruitment visit (Table 1), of which 177 had a new mass (see Supplementary material p5 
for descriptive statistics). Even though conservative management was suggested, 336/3144 
(11%) patients were operated on before any follow-up visit, of which 314 had a newly 
diagnosed mass (Table 2). Of these 314, 13 (4%) were operated on because of suspicion of 
malignancy by the managing clinician and 113 (36%) because of pain (Table 3). Median time 
between recruitment scan and surgery in the 314 patients was 2 months (range 0-47, 
interquartile range 1-4). Stage III primary ovarian cancer was found in one (<1%) patient, 
stage I borderline tumours in two (1%), torsion in seven (2%), and cyst rupture in six (2%) 
patients (Table 3).  
For the 1919 patients with a new mass that actually received follow-up, median follow-up 
was 27 months (interquartile range, 14-38). A histogram showing the follow-up time at all 
patient visits can be found in Supplementary material p10. For patients with a new mass (n = 
1919), the 2-year cumulative incidence for spontaneous resolution was 20·2% (95% CI, 18·4-
22·1), 16·1% (95% CI, 14·3-17·7) for any surgical intervention (Table 4, Figure 2) and 2·0% 
(95% CI, 1·3-2·6) for surgical intervention because of suspected malignancy (Table 4, 
Supplementary material p11). The 2-year cumulative incidences of finding invasive 
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malignancy, a borderline tumour, torsion, or cyst rupture at surgery were 0·4% (95% CI, 0·1-
0·6), 0·3% (95% CI, <0·1-0·5), 0·4% (95% CI, 0·1-0·7), and 0·2% (95% CI, <0·1-0·4), 
respectively (Table 4, Figure 3). Among these 1919 patients, we observed the following 
complications within 24 months of follow-up: seven invasive malignancies (three stage I, two 
stage III, two secondary metastatic tumours), five borderline tumours, seven torsions, and four 
cyst ruptures. Six of the malignancies were diagnosed with surgery within three months after 
inclusion, three after four to six months, two after 11 months, and one after 20 months 
(Supplementary material p6-7). 
The subgroup analysis for pre- and postmenopausal patients who presented with a new mass 
is shown in Supplementary material p8. The absolute number of patients undergoing surgery 
during the first two years of follow-up was 192 and 96 for pre- and post-menopausal patients, 
respectively. 
In Supplementary material p9, we report the cumulative incidences of study outcomes at 12 
and 24 months for patients of all centres, including the 17 centres excluded because they 




Among patients selected for conservative management of an adnexal mass with benign 
ultrasound morphology, the two-year cumulative incidence was 20·2% for spontaneous 
resolution and 16·1% for surgical intervention. The overall two-year cumulative incidence of 
complications was low: 0·4% for invasive malignancy, 0·3% for borderline tumours, 0·4% for 
torsion, and 0·2% for cyst rupture.  
To the best of our knowledge, this is the largest prospective study describing the outcome of 
consecutively recruited conservatively managed adnexal masses. In contrast to most other 
prospective cohort studies17-24, we report results for all patients, including those operated on 
before a follow-up visit despite them having been selected for conservative management. A 
large number of ultrasound centres and operators from different countries and with different 
levels of experience participated, which increases the likelihood of our results being 
generalisable. We applied thorough data cleaning to achieve reliable data, and we present our 
results as cumulative incidences based on survival analysis.  
Unfortunately, a proportion of the patients selected for expectant management was excluded 
or censored in the survival analysis because of loss to follow-up. However, loss to follow-up 
reflects clinical reality. For example, some of the patients referred to a study site for a second 
opinion that were selected for follow-up later opted for management at their primary centre 
because of travel distances or other logistical problems, whilst others moved to another city or 
another country. We made great efforts to minimize loss to follow-up (several rounds of 
queries to study sites and managing clinicians, structured telephone interviews with patients) 
and we included only centres with sufficient quantity and quality of follow-up data in our 
primary analysis. We do not believe that loss to follow-up has resulted in major bias, because 
there were no important differences in patient or tumour characteristics between patients with 




The low risk of complications we have observed shows that conservative management with 
clinical and ultrasound follow-up of adnexal masses with a benign ultrasound appearance is a 
safe management option. In contrast to most previously published studies on follow-up of 
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adnexal masses17-32, our study is prospective, large, multicentre, had very broad inclusion 
criteria and to the best of our knowledge it is the only study that uses survival analysis to 
estimate the risk of complications. It provides the most solid evidence to date of the natural 
history of adnexal masses left in situ.  
Our results are not directly comparable to those in the literature due to differences in inclusion 
criteria, follow-up time and study outcomes. However, in agreement with our results, torsion 
of an adnexal lesion during follow-up is rare in published studies.17,18,22,25,28,29 To the best of 
our knowledge, no published study has reported on cyst rupture. The results of our subgroup 
analysis in premenopausal patients are similar to those in the largest (166 patients) single-
centre study in a comparable population.18 After at least 1 year of follow-up in 134 
postmenopausal patients, Valentin and Akrawi reported a higher rate of spontaneous 
resolution (29·1%) and a lower rate of surgery (9·0%) than in our study.19 The discrepancy 
might be explained at least partly by differences in size and ultrasound morphology of the 
lesions between the two studies. The difference in the rate of surgery between pre- and post-
menopausal patients observed in our study may be explained by differences in indications for 
surgery. Premenopausal patients more often undergo surgery because of pain. They often 
have endometriomas causing pain, while endometriomas are rarely symptomatic in 
postmenopausal patients. The most common indication for surgery during follow-up was 
‘patient request, fertility concerns, opportunistic or prophylactic removal’. Because operative 
risks are generally higher in old than young women, postmenopausal women are less prone to 
request surgery than premenopausal women and doctors are more reluctant to perform surgery 
on old than young women. 
The clinical challenge is to balance any possible benefit of removing presumably benign 
adnexal masses in women with no or minimal symptoms against the risks of surgery. The 
presumed benefit of removing adnexal masses with benign ultrasound morphology is 
prevention of a benign lesion becoming malignant and avoiding leaving a malignant lesion in 
situ because of misdiagnosis. However, in an observational study, in which virtually all 
benign adnexal lesions detected at screening for ovarian cancer were surgically removed, 
ovarian cancer mortality was not lower than expected in the screened population after on 
average 15 years of follow-up.33 Randomised trials on ovarian cancer screening, in which 
substantial numbers of benign lesions were surgically removed, have also not shown a 
reduction of ovarian cancer mortality.4,6 The explanation is probably that ovarian borderline 
tumours and cancers that develop from benign lesions are Type I tumours (low-grade serous, 
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low-grade endometrioid, clear cell, and mucinous). These develop slowly, have a good 
prognosis and account for only a small proportion of ovarian cancer mortality. Type II 
tumours (high-grade serous and undifferentiated carcinomas, and malignant mixed 
mesodermal tumours) may arise from fallopian tube precursors, have aggressive behaviour 
and a less favourable prognosis.34 Out of 1919 patients with a new adnexal mass managed 
conservatively in our study, five were diagnosed with ovarian cancer, five with an ovarian 
borderline tumour, and two with metastases in the ovaries from another primary tumour. All 
but one of the malignancies (a borderline tumour) were surgically removed within one year of 
follow-up, and nine of them within the first six months (Supplementary material p6-7). Four 
of the ovarian cancers were type I (three stage I and one stage III), and one was a type II 
ovarian cancer (stage III) (Supplementary material p6-7). The short time interval between 
recruitment of these patients and diagnosis of malignancy at surgery suggests that these cases 
might represent initial misdiagnosis. Moreover, retrospective review of the ultrasound images 
of the malignant lesions showed that many of them manifested ultrasound signs suspicious for 
malignancy at inclusion and so were misdiagnosed as benign. We find it unlikely that the 
prognosis of the borderline tumours and stage I tumours was made worse by the delay of 
diagnosis. It is difficult to know if and to what extent the prognosis of the two stage III 
ovarian cancers and the two secondary cancers was affected. Longer follow-up than in this 
analysis is needed to estimate the incidence of a change from benign to malignant ultrasound 
morphology in an adnexal mass. The disadvantage of performing surgery on all adnexal 
masses is the risk of short term and long term surgical complications. The reported rates of 
severe surgical complications (e.g. injury to hollow viscus, deep vein thrombosis, pulmonary 
embolism, wound breakdown, bowel obstruction, myocardial infarction) associated with 
removal of benign adnexal masses detected at screening for ovarian cancer in women 50 to 74 
years old are 15·1% (163/1080) and 3·5% (57/1634).4,6 For our own study population, we do 
not have complete information on intra-operative and post-operative surgical complications. 
If the published complication rates apply to our postmenopausal population, and if we had 
operated on all 823 postmenopausal women with a new adnexal mass in our study, then 29 to 
123 of them would have suffered severe surgical complications. Instead, only 96 of them 
(12%) underwent surgery, which means that severe complications were probably avoided in 
between 26 and 109 postmenopausal women. The complication rate associated with adnexal 
surgery in premenopausal women is not well known but is probably lower than in 
postmenopausal women. In addition to intra-operative and postoperative complications there 
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are long term complications, e.g. adhesion formation that may cause bowel obstruction, 
chronic pelvic pain, or fertility problems.  
  
The international multicentre nature of the study and the consecutive recruitment of a large 
number of patients by investigators with different levels of experience make our results highly 
likely to be generalisable. As many as 49·1% of the patients with a newly diagnosed adnexal 
mass were deemed suitable for conservative management at the first visit. However, the 
proportion of patients judged to be suitable for follow-up differed between the centres in our 
study, probably due to differences in patient characteristics and level of experience of 
ultrasound examiners. Not only the ultrasound morphology of an adnexal mass dictates 
management. There may be clinical reasons to opt for conservative management, such as 
comorbidity making the patient unfit for surgery, or previous adnexal surgery resulting in 
reduced ovarian reserve in a premenopausal patient. Based on the results of this interim 
analysis with two years of follow-up, adnexal masses presumed to be benign on ultrasound 
seem suitable for ultrasound and clinical follow-up at intervals of three, six and then 12 
months. Before management recommendations can be made for longer follow-up than two 
years we need to await results on extended follow-up of our conservatively managed patients. 
Future research should also investigate whether the application of objective criteria or 




Knowledge that the risk of malignancy and acute complications is low if adnexal masses with 
benign ultrasound morphology are managed conservatively is of great value when counselling 
patients and supports conservative management of adnexal masses classified as benign using 
ultrasound. This information may lead to a substantial reduction in the number of women who 
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 Table 1. Patients with a mass judged to be benign and selected for conservative management included in 
the study. 
 
Centre N Without follow-
up information   
n (%) 
Operated before  
any follow-up 
n (%) 
Malmo, Sweden 674 16 (2%) 67 (10%) 
Leuven, Belgium 377 12 (3%) 14 (4%) 
Rome, Italy 316 40 (13%) 44 (14%) 
Genk, Belgium 245 24 (10%) 43 (18%) 
Athens, Greece 211 24 (11%) 97 (46%) 
Monza, Italy 209 32 (15%) 10 (5%) 
Stockholm, Sweden 166 4 (2%) 16 (10%) 
Lisbon, Portugal 140 0 8 (6%) 
Milan, Italy 125 9 (7%) 0 
Katowice, Poland 98 10 (10%) 8 (8%) 
Pamplona, Spain 95 19 (20%) 10 (10%) 
London, UK 83 2 (2%) 2 (2%) 
Milan 2, Italy 82 2 (2%) 3 (4%) 
Milan 3, Italy 82 7 (8%) 1 (1%) 
Florence, Italy 62 7 (11%) 4 (6%) 
Trieste, Italy 59 0 4 (7%) 
Tampa, USA 58 6 (10%) 0 
Cagliari, Italy 42 4 (9%) 2 (5%) 
Nottingham, UK 20 
3 (15%) 3 (15%) 















Masses already in 
follow-up 
(n=734)c 
Patient age at recruitment (years) 48 (37-63), 18-98 47 (35-61), 18-98 48 (36-62), 18-98 55 (42-67), 18-93 
Postmenopausal  1429 (45%) 1001 (41%) 823 (43%) 428 (58%) 
Gynaecological symptoms during the year 
preceding inclusion 
1760 (56%) 1358 (56%) 1069 (56%) 402 (55%) 
Time in follow-up at recruitment (months)    18 (6-36), 0·25-266 
Tumour type using IOTA terminology10     
Unilocular 1912 (61%) 1474 (61%) 1149 (60%) 438 (60%) 
Unilocular-solid 138 (4%) 97 (4%) 79 (4%) 41 (6%) 
Multilocular 788 (25%) 601 (25%) 505 (26%) 187 (25%) 
Multilocular-solid 122 (4%) 96 (4%) 80 (4%) 26 (3%) 
Solid 184 (6%) 142 (6%) 106 (5%) 42 (6%) 
Presence of solid components 444 (14%) 335 (14%) 265 (14%) 109 (15%) 
Maximum diameter of lesion (mm) 41 (30-55), 5-456 42 (30-56), 7-456 41 (30-54), 7-216 40 (29-53), 5-157 
Bilateral masses 359 (11%) 269 (11%) 212 (11%) 90 (12%) 
Ultrasound examiner´s subjective impression     
Certainly benign 2282 (73%) 1716 (71%) 1336 (70%) 566 (77%) 
Probably benign 862 (27%) 694 (29%) 583 (30%) 168 (23%) 
Ultrasound examiner´s presumed diagnosis     
Simple/para-ovarian/salpingeal cyst 762 (24%) 583 (24%) 480 (25%) 179 (24%) 
Serous cystadeno(fibr)oma 744 (24%) 511 (21%) 428 (22%) 233 (32%) 
Endometrioma 591 (19%) 458 (19%) 331 (17%) 133 (18%) 
Teratoma 347 (11%) 268 (11%) 195 (10%) 79 (11%) 
Functional cyst 182 (6%) 177 (7%) 158 (8%) 5 (1%) 
Fibro(theco)ma 158 (5%) 116 (5%) 92 (5%) 42 (6%) 
Hydrosalpinx 128 (4%) 104 (4%) 85 (4%) 24 (3%) 
Mucinous cystadeno(fibr)oma 105 (3%) 84 (3%) 67 (3%) 21 (3%) 
Abscess / salpingitis / PID 37 (1%) 34 (1%) 21 (1%) 3 (<1%) 
Inclusion/peritoneal cyst 36 (1%) 26 (1%) 20 (1%) 10 (1%) 
Rare benign tumour 3 (<1%) 2 (<1%) 1 (<1%) 1 (<1%) 
Not possible 51 (2%) 47 (2%) 41 (2%) 4 (<1%) 
Operated on before any follow-up scan 336 (11%) 314 (13%) 0 22 (3%) 
Outcome events observed within 24 months 
after inclusiona 
    
Spontaneous resolution 406 374 374 32 
Surgery performed 685 598 288 87 
Invasive malignancy 11 8 7 3 
Borderline tumour 9 7 5 2 
Torsion 16 14 7 2 
Cyst rupture 12 10 4 2 
Minor mass complicationsb 113 97 47 16 
No mass complications 524 462 218 62 
Death any cause 27 20 20 7 
Results are shown as median (interquartile range), min–max for continuous variables, and as n (%) for categorical variables. 
a We do not provide percentages here, because these do not take follow-up time into account. 
b Includes inflammation/infection or adhesions 
c Includes patients without follow-up after inclusion in the study   
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Table 3. Reason for surgery and histology/surgical findings in patients presenting with a new adnexal 
mass judged to be benign on the basis of ultrasound findings and selected for conservative management 
but operated on before a follow-up visit (n=314).  
 
Surgery findings N 









Major mass complications      
Primary invasive stage 
III 
1 0 0 1 2 
Borderline stage I 2 0 0 2 2 and 3 
Benign histology with 
torsion 
7 0 6 1 1 (0-3) 
Benign histology with 
rupture 
6 0 2 4 2.5 (0-7) 
No major mass 
complications 
     
Endometrioma 75 2 48 25 2 (1-4) 
Simple/parasalpingeal 
cyst 
67 1 19 47 1 (0-3) 
Serous cystadenoma 48 4 9 35 2 (1-3) 
Teratoma 46 1 9 36 2.5 (1-5) 
Mucinous cystadenoma 16 2 6 8 2 (1.75-3.5) 
Hydrosalpinx / 
salpingitis 
14 0 9 5 1 (0-2) 
Physiological cyst 13 1 0 12 1 (0-2) 
Fibroma 12 1 2 9 1 (1-2) 
Abscess 3 0 2 1 0, 3 and 14 
Peritoneal pseudocyst 2 0 1 1 0 and 5 
Rare benign / no 
specific histology 
2 1 0 1 0 and 6 
All 314 13 113 188 2 (range 0-47) 
a Includes patient request/fertility concerns/opportunistic/prophylactic 
b For three or fewer cases the individual numbers are shown, for four or more cases median and range are shown  
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(n = 2587) 
New masses  
(n = 1919) 
12 months 24 months 12 months 24 months 
Cumulative incidence by study outcome     
Spontaneous resolution of cyst 13∙2 (11∙8-14∙5) 16∙3 (14∙8-17∙7) 16∙5 (14∙8-18∙2) 20∙2 (18∙4-22∙1) 
Surgery performed 9∙0 (7∙9-10∙2) 14∙6 (13∙2-16∙0) 10∙3 (8∙9-11∙7) 16∙1 (14∙3-17∙7) 
Death of any cause 0∙5 (0∙2-0∙7) 1∙1 (0∙7-1∙6) 0∙5 (0∙2-0∙8) 1∙2 (0∙6-1∙7) 
Cumulative incidence of surgery by 
indication  
    
Suspicion of malignancy 1∙4 (0∙9-1∙8) 2∙1 (1∙6-2∙7) 1∙4 (0∙9-2∙0) 2∙0 (1∙3-2∙6) 
Pain 2∙6 (1∙9-3∙2) 4∙2 (3∙4-5∙0) 2∙6 (1∙9-3∙4) 4∙5 (3∙5-5∙5) 
Patient request/fertility 
concerns/opportunistic or prophylactic 
removal 
5∙1 (4∙2-6∙0) 8∙2 (7∙1-9∙3) 6∙2 (5∙1-7∙3) 9∙5 (8∙2-10∙9) 
Cumulative incidence of surgery by 
outcome 
    
Invasive malignancy 0∙3 (0∙1-0∙5) 0∙4 (0∙2-0∙7) 0∙4 (0∙1-0∙6) 0∙4 (0∙1-0∙6) 
Borderline tumour 0∙2 (<0∙1-0∙4) 0∙3 (0∙1-0∙5) 0∙2 (<0∙1-0∙4) 0∙3 (<0∙1-0∙5) 
Torsion 0∙2 (<0∙1-0∙4) 0∙3 (0∙1-0∙6) 0∙3 (<0∙1-0∙5) 0∙4 (0∙1-0∙7) 
Cyst rupture 0∙2 (<0∙1-0∙4) 0∙2 (<0∙1-0∙4) 0∙2 (<0∙1-0∙3) 0∙2 (<0∙1-0∙4) 
Minor mass complicationsa 1∙2 (0∙8-1∙6) 2∙5 (1∙8-3∙1) 1∙2 (0∙7-1∙8) 2∙7 (2∙0-3∙5) 
No mass complications 6∙9 (5∙9-7∙9) 10∙8 (9∙6-12∙1) 8∙0 (6∙8-9∙2) 12∙1 (10∙5-13∙6) 
     
Probability of being in follow-upb 77∙3 (75∙6-78∙9) 68∙0 (66∙1-69∙8) 72∙7 (70∙6-74∙6) 62∙5 (60∙2-64∙7) 
Cumulative incidence is shown as percent (95% confidence interval in brackets) 
a Includes inflammation/infection or adhesions 
b The probability of being in follow-up at 12 months or 24 months is the estimated probability of not having a study outcome (spontaneous 
resolution, surgery, or death of any cause) after 12 or 24 months of conservative management. Therefore, it equals 100 minus the sum of the 
cumulative incidences of each study outcome. 
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Figure 2. Cumulative incidence curves of study outcome. This figure is based on patients who presented 
with a new mass and who actually received follow-up (n=1919). Panel A shows the full y-axis (from 0 to 1), 






Figure 3. Cumulative incidence of surgery during follow-up, stratified by surgical outcome. This figure is 
based on patients who presented with a new mass and who actually received follow-up (n=1919). Panel A 
shows the full y-axis (from 0 to 1), panel B is a close up of the curves in panel A. 
 
 
 
 
 
 
 
